JP2010504286A - スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物 - Google Patents

スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物 Download PDF

Info

Publication number
JP2010504286A
JP2010504286A JP2009527532A JP2009527532A JP2010504286A JP 2010504286 A JP2010504286 A JP 2010504286A JP 2009527532 A JP2009527532 A JP 2009527532A JP 2009527532 A JP2009527532 A JP 2009527532A JP 2010504286 A JP2010504286 A JP 2010504286A
Authority
JP
Japan
Prior art keywords
compound
group
mmol
compound according
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009527532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504286A5 (enExample
Inventor
リチャード エル ベアード
ジョン イー ドネロ
ハイキン ユアン
シャオシャ リウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2010504286A publication Critical patent/JP2010504286A/ja
Publication of JP2010504286A5 publication Critical patent/JP2010504286A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
JP2009527532A 2006-09-07 2007-09-05 スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物 Pending JP2010504286A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82480706P 2006-09-07 2006-09-07
PCT/US2007/077588 WO2008030843A1 (en) 2006-09-07 2007-09-05 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity

Publications (2)

Publication Number Publication Date
JP2010504286A true JP2010504286A (ja) 2010-02-12
JP2010504286A5 JP2010504286A5 (enExample) 2010-10-21

Family

ID=38961939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527532A Pending JP2010504286A (ja) 2006-09-07 2007-09-05 スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物

Country Status (6)

Country Link
EP (1) EP2066633A1 (enExample)
JP (1) JP2010504286A (enExample)
AU (1) AU2007292347A1 (enExample)
BR (1) BRPI0716815A2 (enExample)
CA (1) CA2662852A1 (enExample)
WO (1) WO2008030843A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005014271A1 (de) * 2005-03-24 2006-09-28 Rhein Chemie Rheinau Gmbh Mikrogele in Kombination mit funktionalen Additiven
US8563594B2 (en) 2007-05-08 2013-10-22 Allergan, Inc. S1P3 receptor inhibitors for treating pain
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
EP2342205B1 (en) 2008-08-27 2016-04-20 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
IN2012DN05125A (enExample) * 2009-11-24 2015-10-23 Allergan Inc
US8741875B2 (en) 2009-11-24 2014-06-03 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
ES2558087T3 (es) 2010-03-03 2016-02-01 Arena Pharmaceuticals, Inc. Procesos para la preparación de moduladores del receptor S1P1 y formas cristalinas de los mismos
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
US8513220B2 (en) 2010-05-14 2013-08-20 Allergan, Inc. Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity
WO2011143332A1 (en) 2010-05-14 2011-11-17 Allergan, Inc. Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity
US9187437B2 (en) 2010-09-24 2015-11-17 Bristol-Myers Squibb Company Substituted oxadiazole compounds
WO2015089182A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CA3002551A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018151834A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN119751336A (zh) 2018-09-06 2025-04-04 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508845A (ja) * 1990-07-24 1993-12-09 ローン―プーラン・ロレ・ソシエテ・アノニム 選択的ロイコトリエンb4拮抗活性を示す置換2環式ビス―アリール組成物、それらの調製および医薬組成物における使用
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508845A (ja) * 1990-07-24 1993-12-09 ローン―プーラン・ロレ・ソシエテ・アノニム 選択的ロイコトリエンb4拮抗活性を示す置換2環式ビス―アリール組成物、それらの調製および医薬組成物における使用
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN7013000025; Tetrahedron 56, 2000, pp.6319-6330 *
JPN7013000027; J.Org.Chem. 71(16), 2006, pp.5897-5905 *
JPN7013000028; Tetrahedron Letters 31, 1978, pp.2791-2794 *
JPN7013000030; Chem.Pharm.Bull. 13(10), 1965, pp.1168-1177 *
JPN7013000032; Helvetica Chimica Acta 38, 1955, pp.1560-1564 *
JPN7013000034; Chem.Pharm.Bull. 29(10), 1981, pp.2837-2843 *
JPN7013000035; J.Am.Chem.Soc. 78, 1956, pp.2141-2144 *
JPN7013000037; CHEM.COMMUN. , 2002, pp.1760-1761 *

Also Published As

Publication number Publication date
BRPI0716815A2 (pt) 2013-11-05
EP2066633A1 (en) 2009-06-10
WO2008030843A1 (en) 2008-03-13
CA2662852A1 (en) 2008-03-13
AU2007292347A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
JP2010504286A (ja) スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物
KR102872871B1 (ko) 모발 성장을 조절하기 위한 조성물 및 방법
CN101460458A (zh) 具有1-磷酸-鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚-3-羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
US7728014B2 (en) Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity
KR20080102181A (ko) 스핑고신-1-포스페이트 (에스1피) 수용체 길항제 생물학적 활성을 갖는 아릴 또는 헤테로아릴기를 포함하는 인돌-3-카르보실산 아미드, 에스테르, 티오아미드 및 티올 에스테르 화합물
JP2007524682A (ja) 代謝調節型グルタミン酸受容体−5の調節物質としてのビピリジルアミド
BG103689A (bg) Атропизомери на(3)арил-4(3н)-хиназолинони и използването им като амра-рецепторни антагонисти
KR20120129869A (ko) Mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법
RU2641003C2 (ru) Биарильные производные в качестве агонистов gpr120
JP2013525458A (ja) 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体
HRP970261A2 (en) Novel 2, 3 disubstituted-4(3h)-quinazolinones
JP2007504229A (ja) 代謝調節型グルタミン酸受容体−5のモジュレーターとしてのビピリジルアミン類およびエーテル類
CS36192A3 (en) Nitrogen hetero cycles, process of their preparation and pharmaceuticalcompositions containing said hetero cycles
CA2729552A1 (en) Aza-indoles and related compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
JP2010536871A (ja) スフィンゴシン−1−リン酸受容体アゴニストまたはアンタゴニスト生物学的活性を有するピロール化合物
US8507682B2 (en) Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors
CA3194020A1 (en) Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug
FI95372C (fi) Menetelmä valmistaa terapeuttisesti arvokkaita aryylisulfonamideja
JP2010502728A (ja) スフィンゴシン−1−リン酸(s1p)受容体アゴニスト生物活性を有するヘテロ芳香族化合物
RU2052458C1 (ru) Способ получения производных тетразолуксусной кислоты
TW201811754A (zh) 作為d-胺基酸氧化酶(daao)抑制劑之新穎經取代苯并咪唑衍生物
US20120088800A1 (en) 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS
US6825192B1 (en) Heterodiazinone derivatives
EP1142875A1 (en) Cinnamamide derivatives and drug compositions containing the same
CA2083956A1 (en) Amide linked pyridyl-benzoic acid derivatives for treating leukotriene-related diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130610